8082 Federal Register / Vol. 81, No. 31 / Wednesday, February 17, 2016 / Notices 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: February 10, 2016. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2016–03121 Filed 2–16–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Omnibus 

SEP–12. 

Date: March 15, 2016. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, Downtown, 

7335 Wisconsin Avenue, Bethesda, MD 

20814. 

Contact Person: Timothy C. Meeker, MD, 

Ph.D., Scientific Review Officer, Resources 

and Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W624, Rockville, MD 20850, 240– 

276–6464 meekert@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Planning 

Grants for Global Research Infrastructure in 

Non-Communicable Disease. 

Date: April 27–28, 2016. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Courtyard Gaithersburg 

Washingtonian Center, 204 Boardwalk Place, 

Gaithersburg, MD 20878. 

Contact Person: Michael B. Small, Ph.D., 

Chief, Program & Review Extramural Staff 

Training Office, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W412, 

Bethesda, MD 20892–9750, 240–276–6438 

smallm@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: February 10, 2016. 

Melanie J. Gray, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2016–03124 Filed 2–16–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Development of In Vitro 

Diagnostics for the Detection of 

Diseases or Pathogenic Agents 

AGENCY: National Institute of Diabetes 

and Digestive and Kidney Diseases, 

National Institutes of Health, Public 

Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

part 404.7(a)(1)(i), that the National 

Institute of Diabetes and Digestive and 

Kidney Diseases (NIDDK), at the 

National Institutes of Health, 

Department of Health and Human 

Services, is contemplating the grant to 

Altra Tech, Ltd. (‘‘AltraTech’’), a 

company incorporated under the laws of 

the Ireland, having an office in 

Shannon, Ireland, an exclusive patent 

commercialization license to practice 

the following inventions embodied in 

the following patent applications: US 

Provisional Patent Application No.60/ 

846,354, entitled, ‘‘(S,S)-trans-1,2- 

cyclopentane Diamine-modified and 

Gamma-lysine-modified Peptide 

Nucleic Acids as Probes for Nucleic 

Acid Detection: Synthesis and 

Applications,’’ filed 22 Sep 2006 [HHS 

Ref No. E–308–2006/0–US–01]; US 

Provisional Patent Application No. 60/ 

896,667, entitled, ‘‘Synthesis of Transtert-butyl-2- 

aminocyclopentylcarbamate,’’ filed 23 

Mar 2007 [HHS Ref No. E–308–2006/1– 

US–01]; International Application PCT/ 

US2007/020466, entitled, ‘‘Synthesis of 

Trans-tert-butyl-2- 

aminocyclopentylcarbamate,’’ filed 21 

Sep 2007 [HHS Ref No. E–308–2006/2– 

PCT–01]; US Patent Application No. 12/ 

441,925, filed 21 Sep 2007, [HHS Ref 

No. E–308–2006/2–US–02]; US Patent 

Application No. 12/409,159, entitled, 

‘‘Cross-Coupled Peptide Nucleic Acids 

for Detection of Nucleic Acids of 

Pathogens,’’ filed 23 Mar 2009 [HHS Ref 

No. E–308–2006/3–US–01]; US Patent 

No. 9,156,778, entitled, ‘‘Cross-Coupled 

Peptide Nucleic Acids for Detection of 

Nucleic Acids of Pathogens,’’ issued 13 

Oct 2015 [HHS Ref No. E–308–2006/3– 

US–02]; US Provisional Patent 

Application No. 61/684,354, entitled, 

Cyclopentane-peptide Nucleic Acids for 

Qualitative and Quantitative Detection 

of Nucleic Acids,’’ filed 17 Aug 2012 

[HHS Ref No. E–260–2012/0–US–01]; 

International Application PCT/US2013/ 

055252, filed 16 Aug 2013 [HHS Ref No. 

E–260–2012/0–PCT–02]; European 

Patent Application No. 13753962.3, 

filed 11 Feb 2015, [HHS Ref No E–260– 

2012/0–EP–03]; Korea Patent 

Application No. 10–2015–7006286, filed 

11 Mar 2015, [HHS Ref No E–260–2012/ 

0–KR–04]; US Patent Application No. 

14/421,732, filed 13 Feb 2015, [HHS Ref 

No E–260–2012/0–US–05]; US 

Provisional Patent Application No. 61/ 

333,442, filed 11 May 2010, [HHS Ref 

No E–129–2010/0–US–01]; International 

Patent Application No. PCT/US2011/ 

036090, filed 11 May 2011, [HHS Ref 

No. E–129–2010/0–PCT–02]; European 

Patent Application No. 11721899.0, 

filed 11 May 2011, [HHS Ref No. E–129– 

2010/0–EP–03]; and US Patent 

Application No. 13/697,123, filed 9 Nov 

2012, [HHS Ref No. E–129–2010/0–US– 

04]. 

The patent rights in these inventions 

have been assigned to the United States 

of America. AltraTech is seeking a 

worldwide territory for this license. The 

field of use may be limited to exclusive 

use of the licensed patent rights limited 

to the development and sale of transcyclopentane-modified peptide nucleic 

acids (PNA) in a diagnostic test system 

incorporating AltraTech’s proprietary 

sample preparation and AltraTech’s 

proprietary semiconductor sensor 

technology for the detection of 

infectious diseases or pathogenic agents 

including viruses and microorganisms. 

DATES: Only written comments or 

applications for a license (or both) 

which are received by the Technology 

Advancement Office, NIDDK, on or 

before March 3, 2016 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, patents, inquiries, 

comments, and other materials relating 

to the contemplated exclusive license 

should be directed to: Patrick McCue, 

Ph.D., Senior Licensing and Patenting 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 81, No. 31 / Wednesday, February 17, 2016 / Notices 8083 

Manager, Technology Advancement 

Office, The National Institutes of 

Diabetes and Digestive and Kidney 

Diseases, 12A South Drive, Bethesda, 

MD 20892, Telephone: (301) 451–5560; 

Email: patrick.mccue@nih.gov. A signed 

confidentiality non-disclosure 

agreement will be required to receive 

copies of any patent applications that 

have not been published by the United 

States Patent and Trademark Office or 

the World Intellectual Property 

Organization. 

SUPPLEMENTARY INFORMATION: These 

technologies, and the corresponding 

patent applications, are directed to 

cyclopentane-peptide nucleic acids 

(PNA) and their use in qualitative and 

quantitative detection of nucleic acids. 

The technologies overcome a stability 

problem and sensitivity to outside 

contamination that is inherent to PCRbased detection systems, wherein the 

PNA probes bind to DNA with greater 

stability and selectivity compared to a 

complementary DNA sequence. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR part 404. The 

prospective exclusive license may be 

granted unless within fifteen (15) days 

from the date of this published notice, 

the Technology Advancement Office, 

NIDDK, receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404. 

Properly filed competing applications 

for a license in response to this notice 

will be treated as objections to the 

contemplated license. Comments and 

objections submitted in response to this 

notice will not be made available for 

public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: February 10, 2016. 

Anna Amar, 

Acting Deputy Director, Technology 

Advancement Office, NIDDK. 

[FR Doc. 2016–03187 Filed 2–16–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Collaborative Projects in Organ Fibrosis. 

Date: March 8, 2016. 

Time: 8:30 a.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Courtyard by Marriott, 5520 

Wisconsin Avenue, Chevy Chase, MD 20815. 

Contact Person: Kristen Page, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7185, Bethesda, MD 20892, 301–435–0725, 

kristen.page@nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Small Business Point of Care. 

Date: March 9, 2016. 

Time: 9:00 a.m. to 11:00 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Kristin Goltry, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7198, Bethesda, MD 20892, 301–435–0297, 

goltrykl@mail.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Small Business Point of Care. 

Date: March 9–10, 2016. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Kristin Goltry, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7198, Bethesda, MD 20892, 301–435–0297, 

goltrykl@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: February 10, 2016. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2016–03122 Filed 2–16–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PAR–14– 

166: Early Phase Clinical Trials in Imaging 

and Image-Guided Interventions (R01). 

Date: February 29, 2016. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: David L Williams, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5110, 

MSC 7854, Bethesda, MD 20892, (301) 435– 

1174, williamsdl2@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Topics in 

Bacterial Pathogenesis. 

Date: March 9, 2016. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Richard G Kostriken, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3192, 

MSC 7808, Bethesda, MD 20892, 240–519– 

7808, kostrikr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Digestive Sciences. 

Date: March 9, 2016. 

Time: 8:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Cambria Hotel & Suites, 1 Helen 

Heneghan Way, Rockville, MD 20850. 

Contact Person: Martha Garcia, Ph.D., 

Scientific Reviewer Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2186, 

MSC 7818, Bethesda, MD 20892, 301–435– 

1243, garciamc@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 


asabaliauskas on DSK5VPTVN1PROD with NOTICES